We have collected information about Sustained Delivery Formulations Of Risperidone Compounds for you. Follow the links to find out details on Sustained Delivery Formulations Of Risperidone Compounds.
https://patents.google.com/patent/MX337286B/en
The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant.
https://patents.google.com/patent/US9186413B2/en
The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant.Author: Eric Dadey
http://europepmc.org/patents/PAT/US2010266655
The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant.Author: DADEY ERIC
http://europepmc.org/patents/PAT/CA2687979
The sustained r elease delivery system includes a flowable composition containing risperidon e, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injecte d into tissue whereupon it coagulates to become the solid or gel, monolithic implant.Author: DADEY ERIC
http://europepmc.org/patents/PAT/EP2152315
Europe PMC is an ELIXIR Core Data Resource Learn more >. Europe PMC is a service of the Europe PMC Funders' Group, in partnership with the European Bioinformatics Institute; and in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine (NCBI/NLM).It includes content provided to the PMC International archive by participating publishers.Author: DADEY ERIC
http://europepmc.org/patents/PAT/AU2008262545
Sustained delivery formulations of risperidone compounds. PAT - AU2008262545) ...Author: DADEY ERIC
http://www.freepatentsonline.com/y2010/0266655.html
Oct 21, 2010 · This disclosure relates to a risperidone sustained release delivery system for treatment of diseases ameliorated by risperidone compounds. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof.
https://www.sciencedirect.com/science/article/pii/S0939641107002007
The objective of this study was to evaluate a sustained release sucrose acetate isobutyrate (SAIB) in situ system formulation of risperidone (RSP) in vivo. The formulation contained SAIB, ethanol, and polylactic acid (PLA) as a release regulator.Author: Yaxin Lu, Xing Tang, Yue Cui, Yu Zhang, Feng Qin, Xiumei Lu
https://repository.library.northeastern.edu/files/neu:772/fulltext.pdf
24 may also be effectively used in order to slow the release of the active compound, assuming the rate of hydrolysis by the appropriate enzyme is adequately slow11. When used as a release modifier, esters remain as one of the commonly used groups, especially for CNS drug derivatization19.
Searching for Sustained Delivery Formulations Of Risperidone Compounds?
You can just click the links above. The data is collected for you.
